Scarica l'app Stockscreener
0.37
7.48%
-0.0299
Pre-mercato:
.39
0.02
+5.41%
Precedente Chiudi:
$0.3999
Aprire:
$0.4189
Volume 24 ore:
2.64M
Relative Volume:
1.99
Capitalizzazione di mercato:
$115.65M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-18.50
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
-36.27%
1M Prestazione:
-49.86%
6M Prestazione:
-56.11%
1 anno Prestazione:
-41.02%
Intervallo 1D:
$0.3644
$0.4393
Intervallo di 1 settimana:
$0.36
$0.67
Portata 52W:
$0.36
$1.53
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Confronta MCRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.37 | 115.65M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts
MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com
Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World
MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia
MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire
5 Best Microbiome Companies (April 2025) - Securities.io
Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World
Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat
Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World
Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.
Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic? - Yahoo Finance
Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint By Investing.com - Investing.com South Africa
Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Finance
Seres Therapeutics (MCRB) Gets a Hold from Piper Sandler - The Globe and Mail
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com
Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evaluating MCRB’s financial ratios for a profitable investment - US Post News
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq
MCRBSeres Therapeutics Inc Latest Stock News & Market Updates - StockTitan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
New Horizons in Microbiome Therapeutics Whitespace Analysis - openPR
Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World
Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal
Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World
Live Biotherapeutics Market: Rapid Growth Fueled by Microbiome Innovations to Surpass $422.9 Million by 203... - WhaTech
Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):